MDT

83.55

-5.41%↓

VEEV

213.88

-3.96%↓

104.72

-5.07%↓

HQY

78.27

-6.52%↓

PDCO

31.06

-0.58%↓

MDT

83.55

-5.41%↓

VEEV

213.88

-3.96%↓

104.72

-5.07%↓

HQY

78.27

-6.52%↓

PDCO

31.06

-0.58%↓

MDT

83.55

-5.41%↓

VEEV

213.88

-3.96%↓

104.72

-5.07%↓

HQY

78.27

-6.52%↓

PDCO

31.06

-0.58%↓

MDT

83.55

-5.41%↓

VEEV

213.88

-3.96%↓

104.72

-5.07%↓

HQY

78.27

-6.52%↓

PDCO

31.06

-0.58%↓

MDT

83.55

-5.41%↓

VEEV

213.88

-3.96%↓

104.72

-5.07%↓

HQY

78.27

-6.52%↓

PDCO

31.06

-0.58%↓

Начало・Списък с акции・10X Genomics Inc (Class A)

10X Genomics Inc (Class A)

Отворен

СекторЗдравеопазване

7.5 -6.48

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

7.17

Максимум

8.04

Ключови измерители
By Trading Economics
Приходи	-13M -49M
Продажби	13M 165M
EPS	-0.136
Марж на печалбата	-29.71
Служители	1,306
EBITDA	-14M -38M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+84.86% upside

Дивиденти
By Dow Jones
Следващи печалби	29.04.2025 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	1.1B
Предишно отваряне	13.98
Предишно затваряне	7.5

Настроения в новините

By Acuity

100%

374 / 386 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

N/A / 8.54 Подкрепа & съпротива

10X Genomics Inc (Class A) Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

3.04.2025 г., 23:04 ч. UTC

Топ новини

JPMorgan Raises Risk of U.S., Global Recession to 60%

3.04.2025 г., 22:40 ч. UTC

Значими двигатели на пазара

Aldeyra Shares Fall on FDA Complete Response Letter for Dry Eye Disease Drug

3.04.2025 г., 22:18 ч. UTC

Придобивния, сливания и поглъщания

Quantum Corp. Gets Strategic Investment, Names New Financial Chief

3.04.2025 г., 18:51 ч. UTC

Придобивния, сливания и поглъщания

Capital One, Discover Merger Clears Regulatory Hurdle, Sources Tell The New York Times

4.04.2025 г., 00:00 ч. UTC

Топ новини

Resistance Is Futile, Make a Deal: Trump's Tariff Message to the World -- WSJ

3.04.2025 г., 23:43 ч. UTC

Пазарно говорене

Gold Steady, Supported by Potential Safe-Haven Demand -- Market Talk

3.04.2025 г., 23:41 ч. UTC

Пазарно говорене

Nikkei May Fall as U.S. Tariffs Raise Concerns About Global Growth -- Market Talk

3.04.2025 г., 22:22 ч. UTC

Придобивния, сливания и поглъщания

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3.04.2025 г., 22:21 ч. UTC

Придобивния, сливания и поглъщания

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3.04.2025 г., 21:43 ч. UTC

Топ новини

Печалби

The Day Trump's Tariffs Shook Wall Street and Corporate America -- 5th Update

3.04.2025 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

3.04.2025 г., 20:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

3.04.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

3.04.2025 г., 20:43 ч. UTC

Пазарно говорене

Plummeting Toronto Home Sales Reflect Trade, Political Uncertainty -- Market Talk

3.04.2025 г., 20:34 ч. UTC

Топ новини

Trump's Tariffs Were Supposed to Boost the Dollar, But Here's Why the Opposite Happened -- Heard on the Street -- 2nd Update

3.04.2025 г., 20:23 ч. UTC

Топ новини

Trump Tariffs Send Dow Industrials to 1600-Point Decline; Dollar Slumps -- WSJ

3.04.2025 г., 20:15 ч. UTC

Придобивния, сливания и поглъщания

Blackstone Life Sciences And Anthos Therapeutics Announce Novartis Has Completed The Acquisition Of Anthos Therapeutics In A Deal Valued At Up To $3.1B, With $925M Paid Upfront >BX

3.04.2025 г., 19:55 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

3.04.2025 г., 19:55 ч. UTC

Пазарно говорене

Dollar Weakens as Investors Seek Safety Elsewhere -- Market Talk

3.04.2025 г., 19:21 ч. UTC

Пазарно говорене

Oil Futures Slide on U.S. Tariffs, OPEC+ Output Plan -- Market Talk

3.04.2025 г., 19:15 ч. UTC

Пазарно говорене

U.S. Natural Gas Stays Focused on Weather, Storage -- Market Talk

3.04.2025 г., 18:45 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

3.04.2025 г., 18:45 ч. UTC

Пазарно говорене

Gold Drops In Tariff Fallout -- Market Talk

3.04.2025 г., 18:39 ч. UTC

Пазарно говорене

U.S. Tariffs Could Give Natural Gas Edge Over Solar -- Market Talk

3.04.2025 г., 18:38 ч. UTC

Топ новини

Trump Tariffs Send Dow Industrials to 1400-Point Decline; Dollar Slumps -- WSJ

3.04.2025 г., 18:30 ч. UTC

Топ новини

Auto Industry Braces for Major Pain From Trump's Tariffs -- Analysis

3.04.2025 г., 18:20 ч. UTC

Пазарно говорене

Uncertainty Still Roils Companies in Tariff Saga -- Market Talk

3.04.2025 г., 18:18 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

3.04.2025 г., 18:17 ч. UTC

Пазарно говорене

U.S. Workers Can't Match International Labor as Companies Consider Moving Supply Chains -- Market Talk

3.04.2025 г., 18:04 ч. UTC

Пазарно говорене

US Sees More Job Openings in Construction, Transportation -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

10X Genomics Inc (Class A) Прогноза

Ценова цел

By TipRanks

84.86% нагоре

12-месечна прогноза

Среден 16.36 USD 84.86%

Висок 26 USD

Нисък 12 USD

Според 12 анализатори от Wall Street, предложили 12-месечна ценова цел за 10X Genomics Inc (Class A) през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

12 ratings

Купи

Задържане

Продай

Според 12 анализатори, дали борсови рейтинги на 10X Genomics Inc (Class A) през последните 3 месеца.

Техническа оценка

By Trading Central

N/A / 8.54Подкрепа & съпротива

All events are bearish.

Recent bullish events outweigh bearish events.

There are no events.

Настроение

By Acuity

374 / 386 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно 10X Genomics Inc (Class A)

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.